Anti-LXR beta/NER 抗体
Anti-LXR beta/NER antibody
4
(1 Review)
|
(22 Publications)
Rabbit Polyclonal LXR beta/NER antibody. Suitable for WB, ICC/IF and reacts with Human, Mouse, Rat samples. Cited in 22 publications. Immunogen corresponding to Synthetic Peptide within Rat Nr1h2 aa 100-150.
別名を表示する
Lxrb, Nr1h2, Oxysterols receptor LXR-beta, Liver X receptor beta, Nuclear receptor subfamily 1 group H member 2, Orphan nuclear receptor OR-1, Ubiquitously-expressed nuclear receptor, UR
- ICC/IF
Supplier Data
Immunocytochemistry/ Immunofluorescence - Anti-LXR beta/NER antibody (AB28479)
ab28479 staining LXR beta/NER in C2C12 cells by ICC/IF (Immunocytochemistry/immunofluorescence). Cells were fixed with 4% paraformaldehyde, permeabilized with 0.1% Triton X-100 in PBS and blocked with 1% BSA for 1 hour at room temperature. Samples were incubated with primary antibody (2ug/ml) for 3 hours at room temperature. An Alexa Fluor® 488-conjugated Goat anti-rabbit IgG polyclonal was used as the secondary antibody (1/2000). Nuclei stained blue and F-actin stained red. Panel d shows the merged image
- ICC/IF
Supplier Data
Immunocytochemistry/ Immunofluorescence - Anti-LXR beta/NER antibody (AB28479)
ab28479 labelling LXR beta/NER (green) in the nuclear envelope of C2C12 cells (right) compared with a negative control (left) by Immunocytochemistry/Immunofluorescence. Formalin-fixed cells were permeabilized with 0.1% Triton X-100 in TBS for 5-10 minutes, and blocked with 3% BSA-PBS for 30 minutes at room temperature. Cells were incubated with the primary antibody (1 : 200 in 3% BSA-PBS) overnight at 4 °C. A DyLight 488-conjugated Goat anti-rabbit IgG was used as the secondary antibody. Red (phalloidin) - F-actin, Blue (DAPI) - nuclei. Images were taken at a magnification of 60x.
- WB
Supplier Data
Western blot - Anti-LXR beta/NER antibody (AB28479)
A 51 kDa band corresponding to LXR beta was observed across the cell lines and tissue tested.
All lanes:
Western blot - Anti-LXR beta/NER antibody (ab28479) at 2 µg/mL
Lane 1:
Hep G2 nuclear enriched extract at 30 µg
Lane 2:
PC-3 nuclear enriched extract at 30 µg
Lane 3:
3T3-L1 nuclear enriched extract at 30 µg
Lane 4:
Mouse Lung tissue extract at 30 µg
Secondary
All lanes:
Goat anti-Rabbit IgG (H+L) HRP conjugate at 1/4000 dilution
Predicted band size: 50 kDa
false
- WB
Supplier Data
Western blot - Anti-LXR beta/NER antibody (AB28479)
All lanes:
Western blot - Anti-LXR beta/NER antibody (ab28479) at 1/1000 dilution
Lane 1:
Rat liver cell lysate at 25 µg
Lane 2:
Mouse liver cell lysate at 25 µg
Lane 3:
HeLa cell lysate at 25 µg
Secondary
All lanes:
HRP-conjugated anti-rabbit
Predicted band size: 50 kDa
false
- WB
CiteAb
Western blot - Anti-LXR beta/NER antibody (AB28479)
Western Blotting using Anti-LXR beta/NER antibody, ab28479. Publication image from Singh, K. S. et al., 2020, Nat Commun, 31980600. Legend direct from paper.
LXR agonists lower iron content, reverse anti-inflammatory response, and improve Lm killing in S47 mouse macrophages.a Iron accumulation in P47 and S47 MDMs under different treatment conditions by Prussian blue staining. (n = 10 biological replicates, 3–4 fields per sample), Bars, 50 µm. b Iron levels in P47 and S47 MDMs under different treatment conditions measured by loss of calcein fluorescence. Gray histogram = unstained control. (representative from 10 biological replicates). c P47 and S47 mouse splenocytes pretreated with DMSO, GW3965, or T0901317 analyzed for CD4 + , CD25 + and FoxP3-Hi Treg at baseline or in the presence of Lm infection. d Relative protein levels in P47 and S47 mouse MDMs measured by immunoblot after 24 h of indicated treatments. e S47 & P47 mice infected with Lm are treated with PBS or LXR agonist T0901317 and monitored daily from day 2 post infection for survival (n = 5–6 biological replicates) f Spleens of P47 and S47 mice at 9 days post infection. scale = 4 cm. g Bacterial load in different organs at the experimental endpoint measured as CFU/gm (n = 5–6 biological replicates with three technical replicates), compares changes in bacterial load in P47 & S47 mice following T0901317 treatment. Error bars represent means ± s.e.m. P < 0.01, *P < 0.05, ns—not significant; by unpaired Student’s t test, relative to P47 mice. h Arginase activity, i NOS activity, and j Bacterial CFU, measured in P47 (white) and S47 (black) under indicated conditions (n = 5 biological and three technical replicates). Error bars represent means ± s.e.m. ***P < 0.001, **P < 0.01, ns—not significant; by unpaired Student’s t test, relative to P47 mice or to S47 mice where indicated. Source data are provided as a Source Data file.
false
Reactivity data
出荷温度及び保存条件
製品の状態
精製方法
バッファー組成
出荷温度
短期保存温度
長期保存温度
分注に関する情報
保管に関する情報
補足情報
This supplementary information is collated from multiple sources and compiled automatically.
Biological function summary
The protein plays a central role in the maintenance of lipid homeostasis and modulation of inflammatory responses. LXR beta acts within a complex system that also involves other nuclear receptors and co-regulators to effectively control gene transcription. Through its activity LXR beta impacts cholesterol efflux fatty acid synthesis and inflammatory gene expression. It helps preserve cellular lipid balance a critical factor for normal cellular function and overall organism health.
Pathways
LXR beta plays a significant role in the cholesterol metabolism and lipid homeostasis pathways. It activates the transcription of genes like ABCA1 and ABCG1 important for cholesterol efflux in macrophages and other cell types. LXR beta interacts closely with proteins such as SREBP-1c (Sterol Regulatory Element Binding Protein 1c) and RXR which are integral to lipid metabolism pathways. By modulating these pathways LXR beta contributes to reverse cholesterol transport reducing cholesterol overload in cells.
製品プロトコール
- Visit the General protocols
- Visit the Troubleshooting
ターゲットの情報
文献 (22)
Recent publications for all applications. Explore the full list and refine your search
Biochimica et biophysica acta. Molecular basis of disease 1871:167573 PubMed39547517
2024
Applications
Unspecified application
Species
Unspecified reactive species
Inflammation research : official journal of the European Histamine Research Society ... [et al.] 73:157-174 PubMed38183431
2024
Applications
Unspecified application
Species
Unspecified reactive species
Life science alliance 6: PubMed37550000
2023
Applications
Unspecified application
Species
Unspecified reactive species
Investigative ophthalmology & visual science 63:12 PubMed35687344
2022
Applications
Unspecified application
Species
Unspecified reactive species
Data in brief 42:108197 PubMed35515992
2022
Applications
Unspecified application
Species
Unspecified reactive species
Life sciences 277:119464 PubMed33811891
2021
Applications
Unspecified application
Species
Unspecified reactive species
Science advances 6: PubMed33355129
2020
Applications
Unspecified application
Species
Unspecified reactive species
Antioxidants (Basel, Switzerland) 9: PubMed33114278
2020
Applications
Unspecified application
Species
Unspecified reactive species
Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics 17:1253-1270 PubMed32297184
2020
Applications
Unspecified application
Species
Unspecified reactive species
Journal of cellular and molecular medicine 24:5476-5490 PubMed32286000
2020
Applications
Unspecified application
Species
Unspecified reactive species
Abcam product promise
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com